Related Experiment Video
Updated: Nov 4, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
7,8-Dihydroxyflavone suppresses proliferation and induces apoptosis of human osteosarcoma cells
Jing Zhao1, Peifeng Li2, Hua Zhu1
1Department of Pharmacy, Clinical Medical College, Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou 225001, China.
Abstract:
Recent studies suggest that 7,8-dihydroxyflavone (7,8-DHF) inhibits the development of several tumors. However, its role in osteosarcoma (OS) remains unknown. This study was designed to investigate the effects and underlying mechanisms of 7,8-DHF that may influence OS development. Human OS cell lines (U2OS and 143B) were treated with 7,8-DHF; cell viability and cell migration were assessed by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay and wound-healing assay, respectively; and cell death and apoptosis were evaluated by LIVE/DEAD staining and terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay, respectively. Reactive oxygen species production was measured using 2,7-dichlorodihydrofluorescein diacetate probe. Akt, Bcl-xL/Bcl-2 asociated death promoter (Bad), p38 mitogen-activated protein kinase (MAPK), extracellular regulated protein kinase (ERK), and c-Jun N-terminal kinase (JNK) expression and their respective phosphorylation levels were detected by western blot analysis. We found that 7,8-DHF reduced cell viability in a dose-dependent manner and also promoted apoptosis, inhibited migration, and induced oxidative stress in OS cells. Moreover, 7,8-DHF inhibited Akt, Bad, and p38MAPK, but activated ERK and JNK signals. In summary, our results suggest that 7,8-DHF inhibits OS progression, possibly by regulating Akt/Bad and MAPK signaling. These findings provide new evidence for the pharmacological effects of 7,8-DHF that may improve drug therapy for OS patients.
Insights
7,8-dihydroxyflavone (7,8-DHF) inhibits osteosarcoma (OS) progression by reducing cell viability, promoting apoptosis, and inhibiting migration. This natural compound may offer a new therapeutic strategy for OS patients by modulating Akt/Bad and MAPK signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma (OS) is a primary bone malignancy with limited treatment options.
- 7,8-dihydroxyflavone (7,8-DHF), a natural flavonoid, has shown anti-tumor properties in various cancers.
- The role of 7,8-DHF in OS development and its underlying mechanisms are currently unknown.
Purpose of the Study:
- To investigate the anti-cancer effects of 7,8-DHF on human osteosarcoma cell lines.
- To elucidate the molecular mechanisms by which 7,8-DHF influences OS progression.
- To evaluate the potential of 7,8-DHF as a therapeutic agent for osteosarcoma.
Main Methods:
- Human OS cell lines (U2OS, 143B) were treated with 7,8-DHF.
- Cell viability assessed via MTT assay; migration via wound-healing assay.
- Apoptosis, reactive oxygen species (ROS), and signaling pathway proteins (Akt, Bad, MAPK, ERK, JNK) analyzed using TUNEL, fluorescent probes, and Western blot.
Main Results:
- 7,8-DHF significantly reduced OS cell viability and migration in a dose-dependent manner.
- Treatment with 7,8-DHF induced oxidative stress and promoted apoptosis in OS cells.
- 7,8-DHF modulated key signaling pathways, inhibiting Akt/Bad and p38MAPK while activating ERK/JNK.
Conclusions:
- 7,8-dihydroxyflavone demonstrates significant anti-osteosarcoma activity.
- The anti-tumor effects of 7,8-DHF in OS are mediated through the regulation of Akt/Bad and MAPK signaling pathways.
- 7,8-DHF presents a promising candidate for novel therapeutic strategies in osteosarcoma treatment.
More Related Videos
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012